SLU-PP-332 250mcg 60 Oral Capsules

SLU‑PP‑332 is a small-molecule agonist of estrogen-related receptors (ERRα/β/γ), nuclear transcription factors that drive mitochondrial function, fat metabolism, and endurance. Developed at the University of Florida and Saint Louis University, research suggest SLU‑PP‑332 evokes many benefits of aerobic training at the cellular level, making the body behave as if it’s exercising without changes in physical activity or appetite.

Studies are showing promising results, purportedly due to SLU-PP-332 showing the following:
ERR Receptor Agonism – SLU‑PP‑332 binds and activates ERRα, ERRβ, and ERRγ, transcription factors that regulate genes involved in energy metabolism, mitochondrial biogenesis, and oxidative capacity.
Mitochondrial Activation – Drives expression of mitochondrial proteins (e.g., Pdk4), increasing muscle cell respiration and oxidative capacity.
Shift to Fat Oxidation – Triggers systemic metabolic shift toward fatty acid use, increasing energy expenditure and thermogenic-style metabolism.
Enhanced Endurance Mechanisms – Promotes oxidative muscle fibers and endurance adaptations normally induced by aerobic exercise. 

In preclinical studies, the compound was associated with increased energy expenditure, greater fat utilisation, longer running endurance, and reductions in obesity and metabolic-syndrome markers, all while food intake and activity levels were unchanged. It’s being investigated for obesity, age-related muscle decline, and metabolic dysfunction. All current evidence is preclinical (animal and cell studies). Human trials have not yet commenced as of May 2025. SLU‑PP‑332 remains an investigational compound.